GlassScriptPhysician profile
Obinnaya Emerole
NPI 1558314252
$8,062.48
in general payments reported to CMS, 2019-2025
38 companies · $2,820 in 2025
The $2,820 reported for 2025 was more than what 96% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,324 · 2020: $290 · 2021: $553 · 2022: $749 · 2023: $1,352 · 2024: $973 · 2025: $2,820.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,155 · Travel and Lodging: $967 · Education: $23.42.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,154.59 |
| Travel and Lodging | $967.11 |
| Education | $23.42 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Philips North America LLC | $1,855.52 | 2023-2025 | Igt Devices Undivided, Eagle Eye, Coronary Other |
| Boston Scientific Corporation | $685.00 | 2019-2025 | Watchman Flx, Watchman Access System |
| Pfizer INC. | $612.21 | 2020-2025 | |
| Astrazeneca Pharmaceuticals LP | $585.09 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Abbott Laboratories | $387.09 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $364.29 | 2021-2025 | Verquvo, Capvaxive |
| Novartis Pharmaceuticals Corporation | $326.78 | 2019-2024 | |
| Novo Nordisk INC | $303.57 | 2022-2025 | Wegovy |
| Shockwave Medical, INC | $277.38 | 2023-2025 | Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter, Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter |
| Glaxosmithkline, LLC. | $258.57 | 2019-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Alnylam Pharmaceuticals INC. | $234.09 | 2021-2023 | Onpattro, Amvuttra |
| Scpharmaceuticals INC. | $219.41 | 2023-2025 | |
| Heartflow, INC. | $217.24 | 2024-2025 | |
| Medtronic Vascular, INC. | $209.19 | 2019 | |
| Amgen INC. | $201.73 | 2020-2024 | Repatha |
Show all 38 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Obinnaya Emerole listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.